Top Markets
#1 Verus Coin Verus Coin +22.44%
#2 Ontology Gas Ontology Gas +19.53%
#3 Status Status +17.90%
#4 ETHGas ETHGas +15.70%
#5 Geodnet Geodnet +13.21%
#6 Derive Derive +12.82%
#7 Curve DAO Curve DAO +11.62%
#8 Wrapped STX (Velar) Wrapped STX (Velar) +9.94%
#9 Anvil Anvil +9.76%
#10 The Black Bull The Black Bull +9.10%
Coin of the day
Verus Coin Verus Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Arch Biopartners Inc. Arch Biopartners Inc.

Arch Biopartners Inc.

ARCH
Rank in Stocks #25412
Arch Biopartners Inc. is a biotechnology firm dedicated to devising... Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to address or avert dipeptidase-1 driven inflammation in critical organs such as the lungs, liver, and kidneys. This inflammatory response can lead to profound organ dysfunction or complete failure, particularly in conditions like sepsis and COVID-19. Moreover, Arch Biopartners is developing AB569, an experimental medication intended to combat antibiotic-resistant bacterial infections, primarily through topical application on wounds. Their innovative product pipeline also features Borg, a specialized peptide-solid surface interface developed to hinder biofilm formation and lessen material corrosion. Lastly, MetaMx involves synthetic compounds engineered to target the cells that initiate brain tumors and invasive glioma cells. The company's operations are based out of Toronto, Canada.
Share Price
$0.73393689
Last synced: 2026-08-20
Market Cap
$49.86M
Change (1 day)
-8.26%
Change (1 year)
-38.15%
Country
CA
Trade Arch Biopartners Inc. (ARCH)

Category

Healthcare
P/E ratio for Arch Biopartners Inc. (ARCH)
P/E ratio as of 2026 TTM: 0
According to Arch Biopartners Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Arch Biopartners Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.